Conference on Retroviruses and Opportunistic Infections (CROI)

“One size never fits all,” says hepatologist Anna Suk-Fong Lok, MD, emphasizing the need to tailor hepatitis B treatment to fit the patient.

A clinician offers insights on the initial conversations around learning to treat a chronic disease and the importance behind getting patients started down the right treatment path in the early days following a diagnosis.

The Conference on Retroviruses and Opportunistic Infections (CROI) begins today and SARS-CoV-2 has developed into a sustained topic at this annual conference.

Investigators looked at myocardial infarction risks over several years within 2 health care systems examining both people with HIV (PWH) and people without HIV (PWoH).

The investigational therapy has demonstrated promising results utilizing subcutaneous injections every 6 months.

Hispanic/Latino people face disproportionately high HIV incidence, but one CROI 2022 study found those not born in the US are more likely to have stage 3 HIV (AIDS) diagnoses.

Due to policies rolling out HIV pre-exposure prophylaxis (PrEP) and commencing antiretroviral therapy at diagnosis, the UK is on track to eliminate new HIV infections among gay and bisexual men in approximately 25 years.

For people living with HIV (PLWH) an accelerated aging process may affect the severity of their disease.

After presenting at CROI 2022, Dr. Jessica Justman discusses her community-level survey findings: COVID-19 infections do not vary by age.

Investigators looked at full vaccination and booster dose observational data to offer some insights on protection and breakthrough infections.

This patient is the first mixed race woman to experience HIV-1 remission, and potentially opens up the door to others being treated with a novel treatment.

Black patients enrolled in an LA Medical Care Coordination program were less likely to achieve viral suppression than HIV-positive people of other races.

Though HIV diagnoses have declined overall, new infections still disproportionately occur in certain racial, ethic, gender, and geographic populations.

Investigators found a couple of different factors for this phenomenon.

In a global cohort, more than 1 in 3 people living with HIV reported functional impairments. Functional impairment was more common among HIV-positive people who were older, Black, or female.

Data shown in the Pinetree clinical trial and being presented with 2 posters at CROI demonstrate both benefits and safety in preventing progression to more severe disease.

In a study of people living with HIV in Taiwan, COVID-19 vaccination was highly effective when implemented alongside non-pharmaceutical interventions.

Investigators looked to see if this population might be candidates for this form of HIV prevention.

One study presented at CROI 2022 found that HIV PrEP awareness increased among Latinx/Hispanic men who have sex with men, but usage has remained relatively stable for several years.

Boston’s Fenway Health looked at testing and prevention trends during 3 phases of the COVID-19 pandemic.

A comparative study of same-day and seven-day TB test results show there is little difference in HIV treatment adherence or outcomes at 48 weeks.

Phase 1/2 trial results showed the immunomodulary vaccine regimen could induce significant T-cell response in patients with HIV.

A bamlanivimab study showed a 72% reduction in the incidence of COVID-19 and an 80% reduction of progression in the virus in residents in assisted living facilities and nursing staff.

Managing mental health in adults living with HIV is paramount during the COVID-19 pandemic.

While at the earliest stages of potential development, long-acting/extended release (LA/ER) formulations for treatment and prevention of TB could be something to be studied in the future.

Index testing declined in countries including Malawi, Lesotho and Zimbabwe.

Deep learning models identified the largest differences in resting state network topology occurred.

Plasma proteome confirmed the association between cellular and humoral SARS-CoV-2 immunity.

The prognostic proteins identified can serve as the basis of future pathway and network analyses.

Dapivrine (DPV) was studied in 1-month and 3-month durations.